FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force

Epilepsy Curr. 2021 Feb 28;21(3):1535759721996344. doi: 10.1177/1535759721996344. Online ahead of print.

Jacqueline A French^{1

2}, Emilio Perucca³, Josemir W Sander^{4

5

6}, Lennart Bergfeldt^{7

8}, Michel Baulac⁹, David S Auerbach¹⁰, Mark Keezer^{6

11}, Roland D Thijs^{5

6

12}, Orrin Devinsky^{1

2}, David G Vossler¹³, Timothy E Welty¹⁴

¹ Department of Neurology, 5894New York University Grossman School of Medicine, New York, NY, USA.
² NYU, Langone Health, New York, NY, USA.
³ Department of Internal Medicine and Therapeutics, 19001University of Pavia, Pavia, Italy.
⁴ Chalfont Centre for Epilepsy, Chalfont St. Peter, United Kingdom.
⁵ 61554UCL Queen Square Institute of Neurology, London, United Kingdom.
⁶ Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, The Netherlands.
⁷ Department of Molecular & Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, 3570University of Gothenburg, Sweden.
⁸ Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
⁹ Department of Neurology, Salpetrière University Hospital, AP-HP, ICM, 27063Sorbonne Université, Paris, France.
¹⁰ Department of Pharmacology, 12302SUNY Upstate Medical University, Syracuse, NY, USA.
¹¹ Department of Neurosciences & School of Public Health of the 5622Université de Montréal, Montreal, Canada.
¹² Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
¹³ University of Washington, Seattle, WA, USA.
¹⁴ College of Pharmacy and Health Sciences, Drake University, Des Moines, IA, USA.

No abstract available